{"schema_version":"secwatch.filing_event.v1","accession":"0001108205-25-000045","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.542559+00:00","generated_at":"2026-05-22T10:49:50.100950+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Curis Q1 net loss $10.6M, appoints Dr. Hamdy CMO, emavusertib progress","bullets":["Net loss $10.6M ($1.25/share); cash $20.3M; runway into Q4 2025.","Revenue $2.4M from Genentech/Roche Erivedge royalties.","Appointed Dr. Ahmed Hamdy (ex-Pharmacyclics, Acerta) as CMO.","FDA & EMA meetings support accelerated approval path for emavusertib in PCNSL.","Completed registered direct offering and private placement with net proceeds ~$8.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001108205-25-000045","json":"https://secwatch.observer/filing/0001108205-25-000045.json","markdown":"https://secwatch.observer/filing/0001108205-25-000045.md","text":"https://secwatch.observer/filing/0001108205-25-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000110820525000045/0001108205-25-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000110820525000045/cris-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T10:49:50.100950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}